Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 29, 2022 at 06:48 am EDT
Share
Realcan Pharmaceutical Group Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 4,093.5 million compared to CNY 5,764.54 million a year ago. Revenue was CNY 4,093.5 million compared to CNY 5,764.54 million a year ago. Net income was CNY 42.74 million compared to CNY 81.66 million a year ago. Basic earnings per share from continuing operations was CNY 0.03 compared to CNY 0.05 a year ago. Diluted earnings per share from continuing operations was CNY 0.03 compared to CNY 0.05 a year ago.
Realcan Pharmaceutical Group Co., Ltd., formerly REALCAN PHARMACEUTICAL CO., LTD., is a China-based medical service provider. The Company operates its businesses through three segments. The Medical segment is engaged in the provision of Chinese medicine materials, Chinese medicine tablets, Chinese patent medicines, chemical drug materials, chemical preparations, antibiotics, biochemical pharmaceuticals, biological products, psychotropic substances, anesthetic medicines and peptide hormones. The Equipment is engaged in the provision of medical equipment. The Mobile Medical segment is engaged in the provision of medical and logistics services and mobile medical information services. The Company conducts its businesses mainly within domestic markets, with Shandong as its main market.